Results 11 to 20 of about 30,146 (272)

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis [PDF]

, 2018
Innate immunity contributes to the pathogenesis of inflammatory bowel disease (IBD). However, the mechanisms of IBD mediated by innate immunity are incompletely understood and there are limited models of spontaneous innate immune colitis to address this ...
Abernathy-Close, L., Adlaka, K.R., Bakke, D.S., Boger, A.M., Boone, D.L., Iverson, A.M., LaTorre, D.L., Murphy, S.F., Overstreet, A.M., Rhee, L., Weber, C.R.   +10 more
core   +3 more sources

Exploring redox vulnerabilities in JAK2V617F-positive cellular models

Hematology, Transfusion and Cell Therapy, 2021
Background: In Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) models, reactive oxygen species (ROS) are elevated and have been implicated in genomic instability, JAK2/STAT signaling amplification, and disease progression. Although the
Keli Lima, Lucia Rossetti Lopes, João Agostinho Machado-Neto   +2 more
doaj   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +4 more sources

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Frontiers in Oncology, 2021
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but ...
Yingxin Sun, Yingxin Sun, Yifeng Cai, Jia Chen, Jia Chen, Jiannong Cen, Jiannong Cen, Mingqing Zhu, Mingqing Zhu, Jinlan Pan, Jinlan Pan, Depei Wu, Depei Wu, Aining Sun, Aining Sun, Suning Chen, Suning Chen   +16 more
doaj   +1 more source

JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the JAK/STAT and ROS‐MAPK/NF‐κB signalling pathways in acute graft‐versus‐host disease

Clinical & Translational Immunology, 2023
Objectives Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, demonstrates efficacy for treating steroid‐resistant acute graft‐versus‐host disease (SR‐aGVHD) following allogeneic stem cell transplantation (allo‐HSCT).
Yigeng Cao, Jiali Wang, Shan Jiang, Mengnan Lyu, Fei Zhao, Jia Liu, Mingyang Wang, Xiaolei Pei, Weihua Zhai, Xiaoming Feng, Sizhou Feng, Mingzhe Han, Yuanfu Xu, Erlie Jiang   +13 more
doaj   +1 more source

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2022
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary complication of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we retrospectively identified seven patients
Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, Yuanyuan Shi, Lining Zhang, Mengze Hao, Fei Zhao, Rongli Zhang, Jialin Wei, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han   +12 more
doaj   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Frontiers in Endocrinology, 2023
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose
Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher   +3 more
doaj   +1 more source

Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]

, 2016
In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven, Van Vlierberghe, Pieter   +1 more
core   +3 more sources